Join Now

Recent BioUtah News & Events

Everything Happening in Utah Life Sciences

July 17, 2025
BioUtah News
Microvascular Therapeutics Celebrates Major Achievements at ASE 2025 Scientific Sessions

Microvascular Therapeutics Celebrates Major Achievements at ASE 2025 Scientific Sessions

July 10, 2025
BioUtah News
BioSeeker™ Powers Development of a First-of-Its-Kind Programmable Therapeutic for Respiratory Syncytial Virus (RSV)

BioSeeker™ Powers Development of a First-of-Its-Kind Programmable Therapeutic for Respiratory Syncytial Virus (RSV)

July 10, 2025
BioUtah News
Canary Speech Achieves HITRUST e1 Certification for Voice Biomarker Platform

Canary Speech announces it has obtained HITRUST e1 Certification, reinforcing its commitment to cybersecurity related to its voice biomarker technology.

July 10, 2025
BioUtah News
Recursion Acquires Full Rights to REV102, a Potential First-in-Class Oral ENPP1 Inhibitor for Hypophosphatasia

Recursion Acquires Full Rights to REV102, a Potential First-in-Class Oral ENPP1 Inhibitor for Hypophosphatasia

July 10, 2025
Policy News
July 10, 2025
BioUtah News
GE HealthCare’s Economic Impact Across Utah

GE HealthCare’s Economic Impact Across Utah

July 10, 2025
BioUtah News
RefloDx Wins Trans Atlantic Angel Grand Prize

RefloDx Wins Trans Atlantic Angel Grand Prize.

July 9, 2025
Policy News
Webinar Recap: Immigration Compliance Under Pressure

As immigration enforcement and workplace inspections intensify under the current administration, companies in the life sciences sector, particularly those with manufacturing operations, must be proactive in strengthening compliance. Presented by Ogletree Deakin’s Kathleen Weron on July 1, 2025, this webinar provided an overview of the essential components of I-9 compliance, strategies for responding to audits, […]

June 19, 2025
BioUtah News
bioMérieux strengthens its next-generation sequencing capabilities with the acquisition of Day Zero Diagnostics solutions and technologies

bioMérieux strengthens its next-generation sequencing capabilities with the acquisition of Day Zero Diagnostics solutions and technologies

June 19, 2025
BioUtah News
DGENTHERA AND NUSANO SIGN LETTER OF INTENT FOR ASTATINE‑211 SUPPLY

ALPHA-EMITTING RADIOISOTOPE EXPECTED TO PLAY AN ESSENTIAL ROLE IN NEXT-GENERATION TARGETED CANCER THERAPIES

June 19, 2025
Policy News
2025 BIO International Recap

BioUtah and its Utah consortium made their mark this week at the BIO International Conference, hosting a Utah Pavillion to promote the state’s fast-growing life sciences industry. The conference, held in Boston, MA. drew appproximately 20,000 attendees. The Utah delegation included BioUtah, Utah life sciences companies, the Governor’s Office of Economic Development, the Unversity of […]

June 19, 2025
BioUtah News
Halia Therapeutics Completes First-in-Human Phase 1 Study of HT-4253, a Novel LRRK2 Inhibitor Targeting Neuroinflammation

Completion of SAD/MAD trial marks advancement toward further clinical development of HT-4253 in Alzheimer’s and other neurodegenerative diseases.

June 19, 2025
BioUtah News
Nelson Labs to Double Cleanroom Capacity to Support Growing Demand for Sterility Assurance Services

Strategic Expansion in Salt Lake City Headquarters Will Meet Stringent EU GMP Annex 1 Requirements

June 19, 2025
BioUtah News
RATIO THERAPEUTICS AND NUSANO ENTER LONG-TERM, MULTI-ISOTOPE SUPPLY AGREEMENT TO BOOST PRODUCTION OF CANCER RADIOPHARMACEUTICALS

AGREEMENT PROVIDES RATIO ACCESS TO NUSANO-PRODUCED RADIOISOTOPES FOR ONCOLOGY DIAGNOSTICS AND THERAPEUTICS

June 19, 2025
BioUtah News
Microvascular Therapeutics announces Founder and CEO Dr. Evan Unger as panelist in Commercializing SBIR/STTR Technologies Discussion at BIO 2025

Microvascular Therapeutics announces Founder and CEO Dr. Evan Unger as panelist in Commercializing SBIR/STTR Technologies Discussion at BIO 2025

June 12, 2025
BioUtah News
June 12, 2025
BioUtah News
Rebel Medicine Announces Series A Financing and Investigational New Drug (IND) Application Opening to Advance Non‑Opioid Pain Therapeutic into Clinical Development

Rebel Medicine Announces Series A Financing and Investigational New Drug (IND) Application Opening to Advance Non‑Opioid Pain Therapeutic into Clinical Development

June 12, 2025
BioUtah News
NUSANO STABLE ISOTOPE PROGRAM ENRICHES GADOLINIUM-160 TO 99.2% PURITY

DOMESTIC STABLE ISOTOPE PROGRAM KEY TO STABILIZING SUPPLY CHAINS, ENABLING INNOVATION

June 12, 2025
BioUtah News
CancerVax Targets Liver Cancers to Further Showcase Flexibility of Its Universal Platform

Using AI machine learning, the Company discovers distinct biomarkers for detecting certain rare liver cancers that have stem cell characteristics and will include them as additional indications in its preclinical program

June 12, 2025
BioUtah News
Seek Labs Unveils BioSeeker™

Bioseeker™ is the AI Discovery Engine Powering Seek Labs’ Mission to Outpace Disease with Faster, Smarter Global Health Solutions

June 5, 2025
BioUtah News
Halia Therapeutics Completes Enrollment in Phase 2a Clinical Trial of HT-6184 for Myelodysplastic Syndrome (MDS)

Halia Therapeutics Completes Enrollment in Phase 2a Clinical Trial of HT-6184 for Myelodysplastic Syndrome (MDS)

June 5, 2025
BioUtah News
Myriad Genetics Announces Early Access to the FirstGene Multiple Prenatal Screen

Screening test provides prenatal risk assessment for common genetic conditions in one blood draw without the need for paternal testing

June 5, 2025
BioUtah News
Growing collaboration with New York Kidney & Hypertension Medicine

Renalytix collaborates with NYKHM to bring kidneyintelX.dkd testing to underserved communities in the Greater New York area, enabling access for over 2,000 patients.

June 5, 2025
BioUtah News
CancerVax Scientists Featured on Cytiva’s “Discovery Matters” Podcast Discussing Universal Cancer Vaccine Platform

Dr. George Katibah and Dr. Adam Grant describe the features and progress of the Company’s revolutionary technology

May 29, 2025
BioUtah News
Myriad Genetics Highlights New Research Advancements and Oncology Innovations at 2025 ASCO Annual Meeting

Two Molecular Residual Disease (MRD) studies highlighting clinical data among seven new studies to be shared by Myriad and collaborators

May 29, 2025
BioUtah News
BD to Initiate Real-World Patient Data Registry for the Rotarex™ Atherectomy System in Treatment of Peripheral Artery Disease

BD to Initiate Real-World Patient Data Registry for the Rotarex™ Atherectomy System in Treatment of Peripheral Artery Disease

May 29, 2025
BioUtah News
Lessons in Innovation: Clark Turner’s Impact on Medical Imaging

Lessons in Innovation: Clark Turner’s Impact on Medical Imaging

May 22, 2025
BioUtah News
Merit Medical Acquires Biolife Delaware

Acquired business offers the StatSeal® and WoundSeal® products, which provide hemostasis solutions that complement the wide range of procedures Merit’s portfolio supports. Acquisition projected to add approximately $18 million of revenue, on an annualized basis beginning in fiscal year 2026, with a mid-teens growth and accretive non-GAAP margin and profitability profile Merit reaffirms full-year 2025 […]

May 22, 2025
BioUtah News
Pathos AI Secures $365 Million in Series D Financing to Advance Oncology Drug Development Through AI

Pathos AI Secures $365 Million in Series D Financing to Advance Oncology Drug Development Through AI

May 15, 2025
BioUtah News
BD Launches Landmark Cell Analyzer Featuring Breakthrough Spectral and Real-Time Cell Imaging Technologies

New BD FACSDiscover™ A8 Cell Analyzer Brings Leading-Edge Capabilities to Wider Range of Scientists across Academia and Biopharma

May 15, 2025
BioUtah News
KyphoLift Debuts at ISMRM 2025: Transforming Patient Positioning for Safer, More Accurate Imaging

Visit ISMRM Booth H19 for Hands-On Demonstrations of the KyphoLift™ and KyphoWedge™ Systems

May 8, 2025
BioUtah News
Kelvyn Cullimore: An Unfair Penalty on Life-Saving Pills

BioUtah president and CEO, Kelvyn Cullmore, recently penned an op-ed published in the Deseret News.